Standout Papers

Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a ... 2022 2026 2023 2024190
  1. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial (2022)
    David Adams, Ivailo Tournev et al. Amyloid

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 65 standout
Sub-graph 1 of 21

Citing Papers

Targeting and engineering long non-coding RNAs for cancer therapy
2024 Standout
Past, present, and future of CRISPR genome editing technologies
2024 Standout
3 intermediate papers

Works of Seth Arum being referenced

HELIOS-A: RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
2022
HELIOS-A: Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (S8.003)
2022
and 2 more

Author Peers

Author Last Decade Papers Cites
Seth Arum 234 36 60 83 67 24 453
Paulo Gustavo Sampaio Lacativa 115 30 94 68 70 21 418
C M Francucci 126 33 85 56 102 20 454
R Steendijk 124 29 92 50 58 32 436
Nancy Wassef 275 82 122 39 97 21 438
Anaïs Mozar 158 16 207 50 57 16 487
N. Ota 196 49 33 60 91 21 449
Gabriella Aceto 174 66 88 39 27 22 477
Cristina Tau 149 71 38 156 165 16 496
Marja-Kaisa Koivula 116 18 33 68 139 26 406
Sebastian Butscheidt 101 61 42 49 116 31 502

All Works

Loading papers...

Rankless by CCL
2026